Inflation Reduction Act's out-of-pocket cap lowered insulin costs, improved usage for some patients

AI Summary

The Inflation Reduction Act capped insulin out-of-pocket costs at $35 for Medicare beneficiaries, leading to lower costs and increased insulin usage for some US patients, according to a JAMA study. However, these benefits applied only to a small subset of patients.

The Inflation Reduction Act's attempt to improve insulin costs for Medicare beneficiaries—by capping out-of-pocket costs at $35—was associated with lower out-of-pocket costs and increased insulin use, but only for a small portion of U.S. patients, according to a new study published in JAMA.